Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - anastrozole, quantity: 1 mg - tablet, film coated - excipient ingredients: sodium starch glycollate type a; magnesium stearate; lactose monohydrate; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350 - early breast cancer. adjuvant treatment of early breast cancer in postmenopausal women with oestrogen/progesterone-receptor-positive disease. advanced breast cancer. first line treatment of advanced breast cancer in postmenopausal women with oestrogen/progesterone-receptor-positive disease. . treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. patients with oestrogen-receptor-negative disease and patients who have not responded to previous tamoxifen therapy rarely respond to anastrozole.

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - anastrozole 1mg - film coated tablet - 1 mg - active: anastrozole 1mg excipient: hypromellose lactose monohydrate magnesium stearate opadry white y-1-7000 povidone sodium starch glycolate - treatment of advanced breast cancer in post-menopausal women.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - anastrozole, quantity: 1 mg - tablet, film coated - excipient ingredients: sodium starch glycollate; titanium dioxide; lactose monohydrate; magnesium stearate; hydrogenated cottonseed oil; hypromellose; macrogol 6000; pregelatinised maize starch; povidone - early breast cancer. adjuvant treatment of early breast cancer in postmenopausal women with oestrogen/progesterone receptor positive disease. advanced breast cancer. first line treatment of advanced breast cancer in postmenopausal women with oestrogen/progesterone receptor positive disease. treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. patients with oestrogen receptor negative disease and patients who have not responded to previous tamoxifen therapy rarely respond to anastrozole.

Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - anastrozole, quantity: 1 mg - tablet, film coated - excipient ingredients: magnesium stearate; povidone; sodium starch glycollate; lactose monohydrate; titanium dioxide; hypromellose; macrogol 400 - early breast cancer. adjuvant treatment of early breast cancer in postmenopausal women with oestrogen/ progesterone receptor positive disease.. advanced breast cancer. first line treatment of advanced breast cancer in postmenopausal women with oestrogen/ progesterone receptor positive disease.. treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. patients with oestrogen receptor negative disease and patients who have not responded to previous tamoxifen therapy rarely respond to anastrozole.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - anastrozole, quantity: 1 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; hyprolose; magnesium stearate; microcrystalline cellulose; sodium starch glycollate type a; lactose monohydrate; titanium dioxide; hypromellose; macrogol 4000 - early breast cancer: adjuvant treatment of early breast cancer in post-menopausal women with estrogen/progesterone receptor positive disease. advanced breast cancer: first line treatment of advanced breast cancer in post-menopausal women with estrogen/progesterone receptor positive disease. treatment of advanced breast cancer in post-menopausal women with disease progression following tamoxifen therapy. patients with estrogen-receptor-negative disease and patients who have not responded to previous tamoxifen therapy rarely respond to anastrozole.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - anastrozole -

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - anastrozole -

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - anastrozole (unii: 2z07myw1az) (anastrozole - unii:2z07myw1az) - anastrozole 1 mg - anastrozole tablets are indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. anastrozole tablets are indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. anastrozole tablets are indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. patients with er-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets. anastrozole tablets may cause fetal harm when administered to a pregnant woman and offers no clinical benefit to premenopausal women with breast cancer. anastrozole tablets are contraindicated in women who are or may become pregnant. there are no adequate and well-controlled studies in pregnant women using anastrozole tablets. if anastrozole is used during pregnancy, or if the patient becomes pregnant

United States - English - NLM (National Library of Medicine)

a-s medication solutions - anastrozole (unii: 2z07myw1az) (anastrozole - unii:2z07myw1az) - anastrozole 1 mg - anastrozole tablets are indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. anastrozole tablets are indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. anastrozole tablets are indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. patients with er-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets. anastrozole tablets may cause fetal harm when administered to a pregnant woman and offers no clinical benefit to premenopausal women with breast cancer. anastrozole tablets are contraindicated in women who are or may become pregnant. there are no adequate and well-controlled studies in pregnant women using anastrozole tablets. if anastrozole is used during pregnancy, or if the patient becomes pregnant

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - anastrozole, quantity: 1 mg - tablet, film coated - excipient ingredients: lactose monohydrate; povidone; magnesium stearate; sodium starch glycollate type a; hypromellose; titanium dioxide; macrogol 300 - early breast cancer: . adjuvant treatment of early breast cancer in postmenopausal women with oestrogen/progesterone-receptor-positive disease. . advanced breast cancer :. first line treatment of advanced breast cancer in postmenopausal women with oestrogen/progesterone-receptor-positive disease. . treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. patients with oestrogen-receptor-negative disease and patients who have not responded to previous tamoxifen therapy rarely respond to anastrozole.